AstraZeneca Says Forxiga Approved in EU for Heart Failure
07 Fevereiro 2023 - 4:51AM
Dow Jones News
By Kyle Morris
AstraZeneca PLC said Tuesday that Forxiga has been approved in
the European Union for the treatment of symptomatic chronic heart
failure.
The Anglo-Swedish pharma giant said the approval by the European
Commission follows the positive opinion of the Committee for
Medicinal Products for Human Use in December 2022 and was based on
results from the Deliver Phase 3 trial.
Heart failure is a chronic, long-term condition that worsens
over time and affects about 15 million people in Europe, the
company said.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
February 07, 2023 02:36 ET (07:36 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024